from Greenland news--translated
selge upolerte rubiner om få uker ---means raw unpolished rubies will be sold in a few weeks

td is controlling trades

13:53:23 V 0.005 -0.005 25,000 7 TD Sec 7 TD Sec W
10:35:10 V 0.01 37,000 19 Desjardins 19 Desjardins
10:35:10 V 0.01 50,000 19 Desjardins 19 Desjardins
10:35:10 V 0.01 120,000 19 Desjardins 19 Desjardins

also TGX-V widely held it appears by the trading areas
RUBYS

Date Ex Sym Open High Low Close Chg Total Vol #Tr Bid Ask V-TSX-V A-Alpha X-Chi-X H-CX2 P-Pure O-Omega E-TMX Select M-TriAct L-LiquidNet I-Instinet Y-Lynx U-Aequitas
2016-09-09 V TGX 0.005 0.01 0.005 0.005 2,821,425 75 0.005 0.01 1,839,675 100,000 20,000 130,000 404,750 96,000 231,000

can u count 7 markets

true north gems is a producing Vancouver stock

in financial difficulty--they say

CEO is john H and addressed as MS

52 million on 8 exchanges

VOLUME still at zero

that would reduce my potrollio by 360 bucks

many small orders at 11
and the mm;s drove it in that direction

re; TGX.V every late may it drops---MOSQUITOS

some as big as horse-flys

ouch....

8:50AM Theragenics extends exclusivity period under letter agreement with Juniper Investment; Juniper affirms $2.25-$2.30 per share proposal (TGX) 2.03 : Co announced that, based on ongoing discussions, the co and Juniper Investment have agreed to extend the exclusivity period under the letter agreement dated May 12, 2013 in connection with Juniper's proposal to acquire all of the co's outstanding common stock. The exclusivity period will now expire at 5:00 p.m. ET on June 18, 2013 unless, prior to such time, Juniper has provided to the co drafts of equity and debt financing commitments in an amount sufficient to fund the proposed transaction, in which case the exclusivity period will be automatically extended until 5:00 p.m. ET on June 25, 2013.

Juniper has expressly reaffirmed its proposal to acquire all of the co's outstanding common stock for $2.25 to $2.30 per share in cash. In connection with the extension of exclusivity, Juniper's proposal anticipates that any definitive merger agreement between the co and Juniper would contain an appropriate "go shop" provision allowing the co, for a period of 35 days (increased from the 30-day period in Juniper's prior proposal) from the date of execution of a definitive merger agreement, to solicit interest from third parties in connection with an alternative business combination.

7:27AM Theragenics reported Q4 loss of ($0.01) vs the prior year of $0.01; revs fell 4% to $19.1 mln (TGX) 1.65 :

Whats it going to take to get over the 1.6 mark cripes!

7:15AM Theragenics signs brachytherapy loading services agreement with Oncura, a unit of GE Healthcarecs (TGX) 1.56 : Co announced it has signed a value-added loading services agreement with Oncura, a unit of GE Healthcare, to provide worldwide brachytherapy loading services to Oncura. Under the three-year agreement, Theragenics will load and package Oncura manufactured brachytherapy seeds in prescription loaded needles, custom strands and other configurations. Oncura's iodine-125 brachytherapy seeds are utilized primarily in the treatment of early stage prostate cancer. This agreement provides for loading services for most Oncura sales of prescription and custom loaded brachytherapy seeds worldwide, which currently includes North America, Europe, Australia and portions of Asia.

7:17AM Theragenics renews credit agreement; available borrowings increased to $40 mln (TGX) 1.58 : Co announced that it has entered into a Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association. The new three year credit agreement, which is unsecured, replaces the $30 million credit agreement with Wells Fargo that was set to expire on October 31, 2012. Borrowings of $22 million that were outstanding under the old credit agreement have been refinanced under the new $40 million credit agreement. The interest rate on outstanding borrowings under the new credit agreement has been reduced from LIBOR plus 2.25% to LIBOR plus 1.75%. The financial covenants in the new credit agreement are substantially similar to the previous credit agreement.

8:12AM Theragenics announces preliminary results of Dutch Auction tender offer; total of 7,119,345 shares were tendered properly and not withdrawn (TGX) 2.08 : In accordance with the terms and conditions of the offer, and based on the preliminary count by the depositary, Theragenics expects to accept for payment an aggregate of 4.76 mln shares of its common stock at a purchase price of $2.10 per share, for a total cost of ~$10.0 mln , excluding fees and expenses related to the tender offer.

8:32AM Theragenics plans to repurchase up to $10 mln of its shares in a modified dutch auction tender offer (TGX) 1.76 : Co announced it is commencing a modified 'Dutch Auction' tender offer to purchase up to $10 mln of its common stock. Under the terms of the tender offer, Theragenics stockholders will have the opportunity to tender some or all of their shares at a price within a range of $2.00 to $2.40 per share. Based on the number of shares tendered and the prices specified by the tendering stockholders, Theragenics will determine the lowest per share price within the range that will enable it to buy $10 million of its shares, or such lesser number of shares that are properly tendered.

7:11AM Theragenics receives FDA clearance to market Galt VTI valved tearaway introducer (TGX) 1.72 : Co has received FDA 510(k) clearance to market its Galt VTI valved tearaway introducer. Introducers are utilized for vascular access, with the Galt VTI expected to be utilized primarily for placing catheters. The Galt VTI is expected to be launched in the second half of 2012, with revenue in the range of $300,000 expected in this calendar year based on indications of interest from our customer base. Within twelve months of launch, co expects the Galt VTI to generate annualized revenue of $1 million to $2 million, with gross profit margins higher than currently being realized in the Company's Surgical Products segment.

2:06AM Theragenics acquires Core Oncology's prostate brachytherapy customer base; Expected to be accretive to earnings and to generate positive operating cash flow in 2012 (TGX) 1.62 : Co announces that it has purchased Core Oncology's prostate brachytherapy customer base. The asset acquisition was effective on February 17, 2012. The total purchase price is structured as an "earn-out" equal to one times the actual revenue generated from the acquired customers over the twelve month period beginning September 2012 and ending August 2013 in excess of a $2.5 million threshold amount. Theragenics paid $3.8 million in cash at closing as prepayment of a portion of the earn-out, and will make quarterly earn-out payments thereafter. The Company expects to fund the quarterly earn-out payments from operating cash flow and existing cash balances. Additionaly color includes: $5-6 mln of incremental revenue expected in brachytherapy segment for remaining portion of calendar 2012; Expected to be accretive to earnings and to generate positive operating cash flow in 2012; Total earn-out based purchase price is expected to be ~$7.5-10.5 mln, which is based on anticipated revenue in the earn-out period of $10-13 mln from the acquired customers, adjusted for a $2.5 mln threshold amount. Core's prostate brachytherapy sales were ~$13 mln for their fiscal year ended June 30, 2011 and $4 mln for the six months ended December 31, 2011.

~ Monday! $TGX ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $TGX ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=TGX&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=TGX&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=TGX
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=TGX#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=TGX+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=TGX
Finviz: http://finviz.com/quote.ashx?t=TGX
~ BusyStock: http://busystock.com/i.php?s=TGX&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=TGX >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Theragenics Corporation is a medical device company serving the surgical products and cancer treatment markets. The Company operates in two segments: the surgical products segment and the brachytherapy seed segment. Its surgical products business manufactures, markets and sells disposable devices primarily utilized in certain surgical procedures. Its brachytherapy seed business manufactures, markets and sells radioactive seeds primarily utilized in the treatment of early stage prostate cancer. The Company designs, manufactures, assembles, packages and distributes its surgical products in three primary production facilities, each of which manufactures different products. The product lines in its surgical products business include Sutures, Needles and Brachytherapy Accessories, Guidewires, Micro-Introducer Kits, Tearaway Introducer Sets and Kits, Elite HV Introducer Kits and ReDial 4cm High Flow Introducer Sheath.

http://www.google.com/finance?q=TGX